You are here

Article Text

Article menu
Download PDFPDF
Letter
Interferon β-1a treatment of corticosteroid sensitive polymyositis
  1. A Dressel1,
  2. W Beuche2
  1. 1Klinik und Poliklinik für Neurologie, Universität Greifswald, Greifswald, Germany
  2. 2Klinik für Neurologie, Städtisches Klinikum St Georg, Leipzig, Germany
  1. Correspondence to:
 Dr Dressel, Neurologische Klinik, Universität Greifswald, Ellernholzstraβe 1/2, 17487 Greifswald, Germany;
 alexander.dressel{at}neurologie.uni-greifswald.de

https://doi.org/10.1136/jnnp.72.5.676

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Inflammatory myopathies may occur with malignancies or collagenosis (lupus erythematosus, rheumatoid arthritis, overlap syndrome, or mixed connective tissue disease) or be associated with retroviral disease.1 Idiopathic inflammatory myopathies may present as dermatomyositis, inclusion body myositis, or polymyositis.

    Most patients with polymyositis respond well to pulse treatment with corticosteroids. However, this treatment is usually restricted to short periods of time in an effort to contain severe bouts of the disease. A more chronic term of corticosteroid treatment is often desirable but this approach is complicated by untoward side effects and by the tolerability of the patient. Most authors recommend a combination of azathioprine and low doses of corticosteroids. If this regimen fails, ciclosporin A, immunoglobulins, or cyclophosphamide is recommended.2 β Interferons are a new group of immunomodulatory drugs widely used for treatment of patients with multiple sclerosis, a disease of probable autoimmune origin.3 However, no data are available on the efficacy of β interferons in the treatment of other autoimmune diseases.

    Here we report the results of treatment …

    View Full Text